Alzheimer Disease Clinical Trial
Official title:
The Orientation System, the Default-network and Brain Metabolism in Patients With Early Stage Alzheimer's Disease: a Multimodal Functional Study.
Despite the high prevalence of Alzheimer's disease (AD), its underlying mechanisms remain poorly understood. An emerging body of evidence supports disorientation as an early marker for AD-related neurodegeneration. In this study we intend to collect, coregister and analyze Positron Emission Tomography (PET) and , functional and structural magnetic resonance imaging (MRI, fMRI) data from AD-spectrum patients to establish orientation as core disturbance in AD.
As population aging is progressively contributing to the global burden of dementia,
Alzheimer's disease (AD) is gaining recognition as a health-and social-care priority.
Evidence converging from recently published works as well as our own preliminary results,
propose that orientation is a sensitive marker for preclinical AD-related neurodegeneration.
Our behavioral results show a simple orientation test to surpass currently used
neuropsychological tests in classification of patients along the AD spectrum. A
subsequential fMRI study revealed the orientation task to preferentially recruit brain
regions identified as susceptible to early AD-related cortical atrophy, including the
posterior cingulate cortex, parietooccipital sulcus and hippocampus bilaterally, as well as
to significantly overlap with the default mode network (DMN) - a set of interconnected brain
regions which were independently recognized as highly perturbed in AD.
In an attempt to further support the role of orientation in AD we propose to use
co-registration of several modalities of neuroimaging in patients with AD, mild cognitive
impairment (MCI) and healthy controls (HC): resting-state fMRI, task-fMRI, structural MRI
and co-registered PET.
1. Resting-state functional magnetic resonance (fMRI) imaging detecting temporally
synchronous, spatially distributed, spontaneous low frequency blood-oxygen
level-dependent signal fluctuations in task-free settings, that are further clustered
into maps of functional large-scale neural networks. A major network revealed in rest
is the default DMN. DMN includes the posterior cingulate (PCC), inferior parietal
(IPL), lateral (LTC) and medial temporal (MTL), and medial prefrontal cortical regions
(MPFC), and is known to be involved in self-referential processes including
introspection, memory retrieval, daydreaming and orientation.
2. Task fMRI - using this module we recently demonstrated that fMRI activation generated
by orientation task in the person, space and time domains activated the PCC, IPL, and
MPFC and MTL hubs of the DMN. This task is now to be applied in patients with AD.
3. Structural MRI - a decrease in hippocampus volume is an early imaging finding followed
by cortical atrophy as AD progresses.
4. PET - FDG-PET (glucose metabolism) is known to show temporo-parietal hypometabolism in
AD.
Considered these findings alongside ongoing research at the dynamics of anatomical and
functional AD associated brain dysfunction, we propose a thorough, and to the best of our
knowledge, a never before attempted study aimed at linking markers for AD pathology
(cortical atrophy, decrease of functional connectivity, cerebral glucose metabolism) to the
disruption of specific cognitive faculties, particularly orientation in the space, time and
person domains.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |